Many older adults with cancer place more importance on maintaining their independence and cognitive abilities than on living as long as possible.
by Cheryl Platzman Weinstock
Many cancer clinical trials do not track what proportion of enrolled patients are obese, a study finds. These patients may be underrepresented in research.
by Cici Zhang
Researchers are exploring whether wearable personal activity monitors could provide doctors with a more complete picture of cancer patients’ well-being.
by Brad Jones
A study suggests women are more likely than men to undergo genetic testing for mutations linked to hereditary cancer.
In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.
by Kate Yandell
The Biden Cancer Initiative Colloquium gathered experts to discuss obstacles preventing access to care at the AACR Annual Meeting.
by Kevin McLaughlin
At the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.
At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors’ molecular characteristics, not to their tissues of origin.
A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non–small cell lung cancer treatment.
In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
The recently passed Right to Try Act is meant to provide patients with greater access to experimental therapies. Patient advocates are divided on whether the law will benefit patients.
by Marci A. Landsmann
To defend against bacterial infections, cancer patients are often put on a neutropenic diet—which bars fresh fruits and vegetables, among other things. Research indicates that following this diet is unnecessary.
Older melanoma patients may respond to anti-PD1 immunotherapy better than younger patients, a study suggests.
The U.S. Food and Drug Administration approves a targeted therapy combination for thyroid cancer.
Ari M. Melnick, MD, discusses lymphoma research.
The Financial Toll of Cancer
donate to the AACR